Physician
Centric Health
Centric Health was paid $31.48M by Medicaid between Jan 2018 and Dec 2024, across 192 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 29% of everything it billed.
33Billing provider infoCENTRIC HEALTH
BAKERSFIELD, CA 93308
BAKERSFIELD, CA 93308
33aNPI1831248236assigned 01/09/2007
33bProvider typeClinical Cardiac Electrophysiology Physician
28Total paid$31.48M
24GClaims445,917
24DCodes billed192
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinical Cardiac Electrophysiology Physician providers in California
Rank by total paid#1 of 55
Median peer was paid$44K
This provider vs. median710×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 52,526 | $3.20M | |
| 2019 | 59,840 | $3.81M | |
| 2020 | 75,130 | $4.83M | |
| 2021 | 66,639 | $4.48M | |
| 2022 | 57,432 | $4.51M | |
| 2023 | 61,172 | $4.46M | |
| 2024incomplete | 73,178 | $6.19M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 29% | 135,385 | 117,592 | $9.18M |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 16% | 25,339 | 25,070 | $5.19M |
| J2785 | Injection, regadenoson, 0.1 mg | 7.2% | 6,946 | 6,787 | $2.27M |
| 93015 | 6.0% | 13,124 | 12,873 | $1.90M | |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 5.2% | 43,168 | 40,434 | $1.64M |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 4.6% | 10,996 | 10,957 | $1.44M |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | 4.5% | 10,586 | 10,072 | $1.43M |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | 2.5% | 2,165 | 1,997 | $795K |
| 99244 | Office or other outpatient consultation, moderate to high complexity | 1.7% | 4,784 | 4,760 | $531K |
| 93880 | 1.6% | 2,930 | 2,927 | $490K | |
| 99499 | 1.5% | 4,289 | 2,686 | $478K | |
| J0585 | Injection, onabotulinumtoxina, 1 unit | 1.4% | 725 | 370 | $437K |
180 more codes
| 99496 | 1.2% | 1,647 | $386K | |
| 93000 | 1.1% | 11,527 | $340K | |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 8,411 | $270K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 18,311 | $267K |
| 90961 | <1% | 1,481 | $266K | |
| 99205 | Prolong outpt/office vis | <1% | 1,374 | $265K |
| 95912 | <1% | 954 | $264K | |
| 95886 | <1% | 1,170 | $170K | |
| 95251 | <1% | 3,713 | $149K | |
| 99223 | Prolong inpt eval add15 m | <1% | 1,978 | $146K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 1,900 | $143K |
| 93224 | <1% | 1,135 | $143K | |
| 78492 | <1% | 1,736 | $134K | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 1,512 | $129K |
| 93458 | <1% | 690 | $113K | |
| A9555 | Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | <1% | 1,802 | $87K |
| 90960 | End-stage renal disease related services monthly, for patients 20 years and older, with 4 or more face-to-face visits | <1% | 789 | $87K |
| 95910 | <1% | 413 | $84K | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 637 | $80K |
| G9012 | Other specified case management service not elsewhere classified | <1% | 886 | $76K |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 758 | $73K |
| 99495 | <1% | 395 | $70K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 7,955 | $69K |
| 99385 | <1% | 591 | $69K | |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 566 | $66K |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | <1% | 1,471 | $65K |
| 95819 | <1% | 742 | $63K | |
| 93280 | <1% | 1,278 | $54K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 1,125 | $52K |
| 93297 | <1% | 3,059 | $50K | |
| 90962 | <1% | 390 | $49K | |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 1,079 | $48K |
| 71045 | Radiologic examination, chest; single view | <1% | 10,687 | $48K |
| 93295 | <1% | 1,020 | $47K | |
| 93296 | <1% | 2,329 | $46K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 918 | $46K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 6,895 | $44K |
| 93041 | <1% | 3,739 | $43K | |
| 75571 | <1% | 996 | $39K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,990 | $39K |
| 94060 | <1% | 877 | $38K | |
| 64615 | <1% | 322 | $37K | |
| 99245 | <1% | 288 | $33K | |
| 82962 | <1% | 16,056 | $33K | |
| 10005 | <1% | 206 | $32K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 3,300 | $31K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 268 | $31K |
| 93283 | <1% | 443 | $31K | |
| 90756 | <1% | 787 | $29K | |
| 93290 | <1% | 1,245 | $28K | |
| 94618 | <1% | 1,178 | $28K | |
| 99386 | <1% | 253 | $27K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 1,327 | $27K |
| 36573 | <1% | 230 | $26K | |
| 94729 | <1% | 552 | $26K | |
| 94726 | <1% | 547 | $26K | |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 435 | $25K |
| 95911 | <1% | 107 | $25K | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 2,501 | $25K |
| 93298 | <1% | 877 | $24K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 996 | $23K |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 820 | $23K |
| 95816 | <1% | 215 | $22K | |
| 90686 | <1% | 885 | $20K | |
| 92551 | <1% | 1,456 | $19K | |
| 93970 | <1% | 259 | $18K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 282 | $17K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,649 | $17K |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results | <1% | 1,242 | $17K |
| G0442 | Annual alcohol misuse screening, 5 to 15 minutes | <1% | 841 | $17K |
| 93294 | <1% | 818 | $14K | |
| 99384 | <1% | 185 | $14K | |
| 71250 | <1% | 366 | $13K | |
| 81002 | <1% | 6,369 | $11K | |
| 93228 | <1% | 398 | $10K | |
| 90688 | <1% | 417 | $10K | |
| 90966 | <1% | 59 | $10K | |
| 64505 | <1% | 104 | $9K | |
| 20553 | <1% | 180 | $8K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 547 | $8K |
| 76536 | <1% | 125 | $7K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 852 | $7K |
| 99173 | <1% | 1,562 | $7K | |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 173 | $7K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 187 | $7K |
| 0012A | <1% | 174 | $6K | |
| 75574 | <1% | 26 | $6K | |
| 95250 | <1% | 35 | $6K | |
| J0280 | Injection, aminophyllin, up to 250 mg | <1% | 1,166 | $5K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 231 | $5K |
| 95861 | <1% | 44 | $5K | |
| 99152 | <1% | 186 | $5K | |
| 93312 | <1% | 29 | $5K | |
| J1815 | Injection, insulin, per 5 units | <1% | 808 | $5K |
| 90714 | <1% | 124 | $4K | |
| 0011A | <1% | 156 | $4K | |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 124 | $3K |
| 36005 | <1% | 36 | $3K | |
| 76937 | <1% | 529 | $3K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 34 | $3K |
| 93282 | <1% | 45 | $3K | |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 27 | $3K |
| 93299 | <1% | 402 | $2K | |
| 36410 | <1% | 357 | $2K | |
| 71270 | <1% | 12 | $2K | |
| 94750 | <1% | 107 | $2K | |
| 99221 | <1% | 54 | $2K | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 351 | $2K |
| 93284 | <1% | 24 | $2K | |
| 93925 | <1% | 12 | $1K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 178 | $1K |
| G9007 | Coordinated care fee, scheduled team conference | <1% | 26 | $1K |
| 94200 | <1% | 264 | $1K | |
| 90658 | <1% | 44 | $1K | |
| 96127 | <1% | 211 | $1K | |
| 90674 | <1% | 32 | $1K | |
| 93320 | <1% | 14 | $1K | |
| 99243 | <1% | 13 | $884.60 | |
| G8510 | Screening for depression is documented as negative, a follow-up plan is not required | <1% | 48 | $822.72 |
| 99153 | Mod sedat endo service >5yrs | <1% | 87 | $757.64 |
| 3046F | <1% | 233 | $605.06 | |
| 93325 | <1% | 14 | $600.26 | |
| 94664 | <1% | 252 | $581.12 | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 12 | $569.66 |
| 93244 | <1% | 30 | $516.53 | |
| 36569 | <1% | 16 | $511.93 | |
| 74022 | <1% | 12 | $496.68 | |
| 80053 | Comprehensive metabolic panel | <1% | 46 | $413.55 |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 30 | $413.28 |
| 93242 | <1% | 31 | $394.11 | |
| 94010 | <1% | 14 | $383.76 | |
| 85018 | <1% | 236 | $383.39 | |
| 93307 | <1% | 26 | $322.75 | |
| 80061 | Lipid panel | <1% | 26 | $288.50 |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 16 | $277.30 |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 12 | $256.57 |
| 76775 | <1% | 13 | $255.47 | |
| J7611 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg | <1% | 514 | $252.06 |
| 3044F | <1% | 278 | $194.67 | |
| 71010 | <1% | 28 | $183.01 | |
| 84480 | <1% | 14 | $163.67 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 74 | $158.85 |
| 99490 | Ccm add 20min | <1% | 647 | $143.87 |
| 99443 | <1% | 71 | $136.20 | |
| 3051F | <1% | 94 | $131.97 | |
| 99072 | <1% | 1,893 | $130.00 | |
| 1036F | <1% | 2,419 | $110.60 | |
| 3017F | <1% | 522 | $105.56 | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 16 | $104.61 |
| 84439 | <1% | 14 | $102.83 | |
| 76942 | <1% | 16 | $90.64 | |
| 1160F | <1% | 26 | $64.81 | |
| 1159F | <1% | 27 | $64.74 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 13 | $55.07 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 14 | $48.09 |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 152 | $45.98 |
| 1124F | <1% | 92 | $41.27 | |
| Q0091 | Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | <1% | 26 | $39.41 |
| 1111F | <1% | 1,017 | $38.95 | |
| G8427 | Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications | <1% | 1,229 | $38.95 |
| 99442 | <1% | 45 | $37.72 | |
| 73630 | <1% | 15 | $35.26 | |
| G0101 | Cervical or vaginal cancer screening; pelvic and clinical breast examination | <1% | 26 | $33.35 |
| 88738 | <1% | 520 | $24.28 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 1,357 | $24.24 |
| G0008 | Administration of influenza virus vaccine | <1% | 44 | $17.35 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,207 | $5.35 |
| 1126F | 0% | 270 | $0.00 | |
| 3052F | 0% | 12 | $0.00 | |
| 3074F | 0% | 344 | $0.00 | |
| 99224 | 0% | 14 | $0.00 | |
| 3079F | 0% | 92 | $0.00 | |
| 1125F | 0% | 23 | $0.00 | |
| G9903 | Patient screened for tobacco use and identified as a tobacco non-user | 0% | 15 | $0.00 |
| G8754 | Most recent diastolic blood pressure < 90 mmhg | 0% | 12 | $0.00 |
| 3078F | 0% | 337 | $0.00 | |
| 97602 | 0% | 25 | $0.00 | |
| G8783 | Normal blood pressure reading documented, follow-up not required | 0% | 14 | $0.00 |
| 3077F | 0% | 36 | $0.00 | |
| 4004F | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBHAMBI, BRIJESH (MANAGING PARTNER)
| Provider | Location | Paid |
|---|---|---|
| Centric Health | Bakersfield, CA | $7.01M |
| Centric Health | Bakersfield, CA | $194K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.